Immune-Related Adverse Events of Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Immune-Related Adverse Events of Immune Checkpoint Inhibitors

Published:2024-02 Issue:2 Volume:177 Page:ITC17-ITC32
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Ramos-Casals Manuel¹^ORCID,Sisó-Almirall Antoni²^ORCID

Affiliation:

1. Department of Autoimmune Diseases, ICMiD, Hospital Clínic, and Department of Medicine, University of Barcelona, Barcelona, Spain (M.R.)

2. Department of Medicine, University of Barcelona; Primary Healthcare Transversal Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain (A.S.)

Publisher

American College of Physicians

Link

https://www.acpjournals.org/doi/pdf/10.7326/AITC202402200

Reference61 articles.

1. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

2. The blockade of immune checkpoints in cancer immunotherapy

3. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

4. The evolutionary legacy of immune checkpoint inhibitors

5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment;Cancer Drug Resistance;2024-09-13

2. Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial;eClinicalMedicine;2024-09

3. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database;Antibodies;2024-07-17

4. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment;Cancer Letters;2024-07

5. Oncology: What You May Have Missed in 2023;Annals of Internal Medicine;2024-05